Tomoyuki Araya

531 total citations
33 papers, 356 citations indexed

About

Tomoyuki Araya is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Tomoyuki Araya has authored 33 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Tomoyuki Araya's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Tomoyuki Araya is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Tomoyuki Araya collaborates with scholars based in Japan and United Kingdom. Tomoyuki Araya's co-authors include Kazuo Kasahara, Hideharu Kimura, Shinji Nakao, T. Sone, Kazuto Nishio, M Fujimura, K Miyamoto, Fumiaki Koizumi, Toshiyuki Kita and Hiroki Matsuoka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Tomoyuki Araya

29 papers receiving 349 citations

Peers

Countries citing papers authored by Tomoyuki Araya

Since Specialization

Citations

This map shows the geographic impact of Tomoyuki Araya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoyuki Araya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoyuki Araya more than expected).

Fields of papers citing papers by Tomoyuki Araya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoyuki Araya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoyuki Araya. The network helps show where Tomoyuki Araya may publish in the future.

Co-authorship network of co-authors of Tomoyuki Araya

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoyuki Araya. A scholar is included among the top collaborators of Tomoyuki Araya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoyuki Araya. Tomoyuki Araya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study 2025 ·Lung Cancer ·Yuichi Tambo, Takashi Sone, Koichi Nishi, Kazuhiko Shibata, Toshiyuki Kita, Tomoyuki Araya, (unknown), (unknown), (unknown), Hiroki Matsuoka, (unknown), Hayato Koba, (unknown), (unknown), Seiji Nomura, (unknown), (unknown)	2
2	Tumor-to-Tumor Metastasis of Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma to a Meningioma 14 Years After Curative Lobectomy: A Case Report 2025 ·Cureus ·(unknown), Tomoyuki Araya, Takayuki Higashi, (unknown), Toshiyuki Kita	1
3	Large lung mass lesion with spontaneous regression in a patient with IgG4‐related lung disease 2022 ·SHILAP Revista de lepidopterología ·(unknown), Tomoyuki Araya, Toshiyuki Kita, (unknown)	1
4	Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings 2022 ·Clinical Lung Cancer ·(unknown), Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, (unknown), (unknown), Tomoyuki Araya, Toshiyuki Kita, (unknown), (unknown), (unknown), Shingo Nishikawa, Yuichi Tambo, Hideharu Kimura, Kazuo Kasahara	13
5	Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma 2021 ·The American Journal of the Medical Sciences ·Toshiyuki Kita, Tomoyuki Araya, (unknown), Yuka Uchida, Hiroki Matsuoka, Kazuo Kasahara	7
6	Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series 2021 ·Translational Lung Cancer Research ·Hideharu Kimura, Takashi Sone, Tomoyuki Araya, (unknown), (unknown), Noriyuki Ohkura, Johsuke Hara, Miki Abo, Kazuo Kasahara	4
7	Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression 2020 ·Clinical Lung Cancer ·Yuichi Tambo, Takashi Sone, Kazuhiko Shibata, (unknown), (unknown), (unknown), Tomoyuki Araya, (unknown), Shingo Nishikawa, Hideharu Kimura, Kazuo Kasahara	27
8	Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus <b><i>nab</i></b>-Paclitaxel and Maintenance Monotherapy with <b><i>nab</i></b>-Paclitaxel: Two Case Reports 2020 ·Case Reports in Oncology ·Tomoyuki Araya, Toshiyuki Kita, Hiroki Matsuoka, (unknown), Hideharu Kimura, Kazuo Kasahara	3
9	Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status 2019 ·Journal of Cancer ·(unknown), Yukio Suga, Tomoyuki Araya, Toshiyuki Kita, (unknown), Nobuyoshi Tanaka, (unknown), (unknown), (unknown)	16
10	IgG4-Related Pleuritis With No Other Organ Involvement 2018 ·The American Journal of the Medical Sciences ·Toshiyuki Kita, Tomoyuki Araya, Yukari Ichikawa, (unknown), Atsuhiro Kawashima, Satomi Kasashima, Kazuo Kasahara	15
11	18F-FDG uptake predicts diagnostic yield of transbronchial biopsy in peripheral lung cancer 2014 ·Lung Cancer ·Yukihiro Umeda, Yoshiki Demura, Masaki Anzai, Hiroki Matsuoka, Tomoyuki Araya, Masaru Nishitsuji, Koichi Nishi, Tatsuro Tsuchida, (unknown), Miwa Morikawa, Shingo Ameshima, Takeshi Ishizaki, Kazuo Kasahara, Tamotsu Ishizuka	8
12	Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice 2013 ·OncoTargets and Therapy ·Tomoyuki Araya, (unknown), Nishikawa, K Kimura, (unknown), (unknown), (unknown), (unknown), (unknown)	16
13	Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer 2013 ·Lung Cancer ·Tomoyuki Araya, Kazuo Kasahara, Yoshiki Demura, Hiroki Matsuoka, Masaru Nishitsuji, Koichi Nishi	3
14	Usefulness of Transesophageal Bronchoscopic Ultrasound-guided Fine-Needle Aspiration in the Pathologic and Molecular Diagnosis of Lung Cancer Lesions Adjacent to the Esophagus 2013 ·Journal of Bronchology & Interventional Pulmonology ·Tomoyuki Araya, Yoshiki Demura, Kazuo Kasahara, Hiroki Matsuoka, (unknown), Masaru Nishitsuji, Koichi Nishi	25
15	Two Cases of Small Cell Lung Cancer with Metastasis to the Stomach at Initial Diagnosis 2012 ·Haigan ·Akihito Okazaki, Tomoyuki Araya, (unknown), Takashi Sone, Kazuo Kasahara, Masaki Fujimura	1
16	Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial 2007 ·Lung Cancer ·Tomoyuki Araya, Kazuo Kasahara, Hideharu Kimura, Kazuhiko Shibata, Toshiyuki Kita, (unknown), Johsuke Hara, (unknown), Takashi Sone, (unknown), (unknown), (unknown), Masaki Fujimura, Shinji Nakao	6
17	P3-103: Evaluation of Epidermal Growth Factor Receptor Mutation Status in Serum DNA as a Predictor of Response to Gefitinib (IRESSA) 2007 ·Journal of Thoracic Oncology ·Hideharu Kimura, (unknown), Kazuo Kasahara, Takashi Sone, Tomoyuki Araya, (unknown), Kazuto Nishio, Ken‐ichi Miyamoto, Masaki Fujimura	2
18	P2-312: A retrospective study of salvage chemotherapy for advanced non-small cell lung cancer; the efficacy of third and fourth chemotherapy. 2007 ·Journal of Thoracic Oncology ·Yuichi Tambo, Kazuo Kasahara, Hideharu Kimura, Takashi Sone, Tomoyuki Araya, (unknown), Masaki Fujimura, Shinji Nakao	1
19	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) 2007 ·British Journal of Cancer ·Hideharu Kimura, (unknown), Kazuo Kasahara, T. Sone, Tomoyuki Araya, (unknown), Fumiaki Koizumi, Kazuto Nishio, K Miyamoto, M Fujimura, Shinji Nakao	171
20	A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC) 2004 ·Journal of Clinical Oncology ·Kazuo Kasahara, T. Sone, Hideharu Kimura, Akihiro Yoshimoto, Tomoyuki Araya, Kazuo Iwasa, (unknown), (unknown), M Fujimura, Shinji Nakao	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact